This site uses cookies, including third-party cookies, that help us to provide and improve our services. Read More

Oncology Small Molecule Drugs Market

Oncology Small Molecule Drugs Market

Rising Prevalence of Cancer with Demand for Effective Drugs to Boost the Oncology Small Molecule Drugs Market Growth during 2021-2031

Oncology Small Molecule Drugs Market
  • Aug-2021
  • List of Tables : 53
  • List of Figures : 215
  • 170 Pages
  • Healthcare

Market Snapshot

Revenues in the targeted therapy drugs segment of the oncology small molecule drugs industry is expected to showcase robust expansion through 2021. As of 2019, market revenue for the overall market surpassed US$ 66 Bn, up from US$ 63 Bn in 2018. The market will remain consolidated, with top five players, Novartis Ag, AstraZeneca, Genentech, Pfizer, and AbbVie, accounting for 47% market share. 

Key Points Covered in Oncology Small Molecule Drugs Industry Survey:

  • Market Estimates and Forecasts 2016-2031
  • Key drivers and restraints shaping market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Oncology Small Molecule Drugs Market and How to Navigate
  • Recommendation on a Key Winning Strategies

Know More Details About the Report

Consumption Analysis of Oncology Small Molecule Drugs 2016-2020 Vs Future Outlook 2021 to 2031

From 2016 to 2020, demand for oncology small molecule drugs surged at nearly 3% CAGR, reaching over US$ 66 Bn. The market was valued at nearly US$ 63 Bn in 2018, attributed by widespread prevalence of cancer and subsequent need for oral, easily absorbable, and effective medicines.

The market for oncology small molecule drugs is predicted to surpass US$ 120 Bn by 2031 surpassing a CAGR of 6% in the forecast period. Rapid technological advancement in healthcare sector is foresee to be the primary demand driving determinant.

Furthermore, North America, led by the U.S., is predicted to remain the dominant market for oncology small molecule drugs during the foreseeable period. Owing to high drug cost and favourable reimbursement scenarios for cancer treatment, the US is predictable to witness revenues worth around US$ 30 Bn in 2019.

What are the Factors Driving the Demand for the Oncology Small Molecule Drugs Market?

Rising awareness about the availability of innovative and easy intake drugs for cancer treatment is providing a stimulus to oncology small molecule drugs sales. Furthermore, high prevalence of cancer, coupled with growing demand for effective drugs are the prominent demand drivers for oncology small molecule drugs.

Additionally, rapid technological advancements in healthcare sector and surging demand for outsourcing clinical trials is projected to accelerate the market growth in the forthcoming period.

Avail customized purchase options for your needs

How are Regulatory Approvals for Various Formulations Widening Prospects?

In 2020, the U.S Food & Drug Administration (FDA)  approved 4 novel drugs for patients with lung cancer (pralsetinib, lurbinectedin, selpercatinib, capmatinib), in addition to several expansions for the use of previously approved therapeutics. Manufacturers are incorporating modern equipments to reduce the risk and effective treatment of cancer.

Moreover, governments are investing in research and development of advanced cancer drugs that can be economical and easily available worldwide in order to pull down the mortality rate

How will Changing Trends Impact the Oncology Small Molecule Drugs Market?

Expanding research and development (R&D) activities for targeted therapies such as hormone therapies, signal transduction inhibitors and immunotherapies among research centres are boosting the growth of oncology small molecule drugs market. 

Furthermore, manufacturers are leveraging next-generation technology such as artificial intelligence (AI) to optimize time and reduce development cost of cancer drugs across the forecast period.

An Adaptive Approach to Modern-day Research Needs

Country-wise insights

How are Regulatory Approvals Widening Sales in the U.S Market?

As per the American Cancer Society as of 2020, nearly 1.8 million new cancer cases were predicted to be diagnosed, with around 606,520 fatalities across the U.S. To prevent this, pharmaceutical companies are pushing for faster approvals of their potential drug candidates, widening prospects.

However, subsequent approval of cancer drugs by FDA has paved for the market expansion of oncology targeted drugs in the country. Additionally, manufacturers are focusing on technological advancements in drug development cycle which will optimize the discoveries of new and effective drugs.

With high treatment seeking rate and favorable reimbursement scenarios for cancer treatment, the U.S is estimated to witness revenues worth US$ 30 Bn in 2019.

Why is the Oncology Small Molecule Drugs Industry Flourishing in China?

China stands second in the market, with its oncology market alone encompassing 37% of all lung cancer, 44% of stomach cancer and 52% of liver cancer patients globally. Additionally, China’s cancer mortality rate is 40% higher than that of the U.S. rate.

Recently, China has granted the first full approval of a drug developed in the country to have been through modern clinical trials: the colorectal cancer treatment Elunate (fruquintinib). This will help the oncology small molecule drugs industry to flourish in the country. Nearly 55% of global demand will emanate from China.

Category-wise insights:

Why are Oral Oncology Small Molecule Drugs More Preferred?

Sales of oral oncology drugs amounted to over US$ 56 Bn in 2019. According to NIH, oral targeted therapies are increasingly being used to treat cancer. They work by interfering with specific molecules or pathways involved in tumour growth.

Currently, targeting drug delivery is emerging as an effective approach for oral delivery of different therapeutics. North America was the largest region in the global oral oncology drugs market, accounting for 46% of the market in 2019, followed by Asia at 24%.

How are Targeted Therapy Drugs Emerging as a Dominant Category?

Targeted therapy as a vital type of cancer treatment continues to expand the bandwidth of opportunities as they can help stop a cancer cell from dividing and making new cancer cells. As per Fact.MR, targeted therapy drugs are expected to capture nearly 50% of the global revenue.

Mounting FDA approvals of oncology small molecule drugs, such as larotrectinib (Vitrakvi) as a type of targeted therapy that aims a specific genetic change known as NTRK fusion, continue to add gains into the market.

Meanwhile the first tyrosine kinase inhibitor imatinib was approved market sales by the US Food and Drug Administration (FDA) in 2001, a swelling number of small-molecule targeted drugs have been developed for the treatment of malignancies. Targeted drugs have rapidly developed and entered a golden period of development.

Have a report related query? Speak to us directly

Competitive Landscape

Prominent players are embracing innovative approaches such as ground-breaking marketing tactics, technological advancements, mergers, and acquisitions.   

  • In June 2021, Novartis AG has received breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental treatment for advanced castration-resistant prostate cancer-Novartis’ Lu-PSMA-617 - a tumour-targeting radiation therapy
  • In December 2019, Sanofi and Synthorx, Inc., a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement of approximately $2.5 Bn (on a fully diluted basis).

Report Scope

Report Attribute


Market size value in 2020

USD 66 Billion

Market forecast value in 2031

USD 120 Billion

Growth Rate

CAGR of 6% from 2021 to 2031

Forecast Period


Historical Data Available for


Market Analysis

US$ Mn for Value & ‘000 Units for Volume

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Countries Covered

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • Italy
  • France
  • Spain
  • Russia
  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC
  • Turkey
  • South Africa

Key Market Segments Covered

  • Route of Administration
  • Drug Class
  • Distribution Channel
  • Indication
  • Region

Key Companies Profiled

  • Novartis AG
  • Pfizer Inc.
  • Amgen Plc.
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Sanofi SA
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Bayer AG
  • Incyte Corporation
  • Celgene Corporation
  • AstraZeneca Plc.
  • Exelixis Inc.
  • Millennium Pharmaceuticals Inc. (Takeda)


Available upon Request

Key Segments Covered

  • Route of Administration

    • Oral Oncology Small Molecule Drugs
    • Injectable Oncology Small Molecule Drugs
  • Drug Class

    • Small Molecule Chemotherapy Drugs
      • Alkylating Drugs
      • Antimetabolites
      • Other Drugs
    • Small Molecule Immunomodulating Drugs
    • Small Molecule Targeted Therapy Drugs
      • Proteasome Inhibitors
      • Tyrosine Kinase Inhibitors
      • mTOR Inhibitors
      • Hormonal Therapy
  • Distribution Channel

    • Oncology Small Molecule Drugs Distribution via Hospital Pharmacies
    • Oncology Small Molecule Drugs Distribution via Retail Pharmacies
    • Oncology Small Molecule Drugs Distribution via Specialty clinics
    • Oncology Small Molecule Drugs Distribution via Online Pharmacies
  • Indication    

    • Oncology Small Molecule Drugs  for Non-small Cell Lung Cancer
    • Oncology Small Molecule Drugs  for Renal Cell Carcinoma
    • Oncology Small Molecule Drugs  for Breast Cancer
    • Oncology Small Molecule Drugs  for Prostate Cancer
    • Oncology Small Molecule Drugs  for Multiple Myeloma
    • Oncology Small Molecule Drugs  for Melanoma
    • Oncology Small Molecule Drugs  for Lymphoma
    • Oncology Small Molecule Drugs  for Leukaemia
    • Oncology Small Molecule Drugs  for Other Indications           

Oncology Small Molecule Drugs Market- Scope of Report

A recent study by Fact.MR on the oncology small molecule drugs market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging associated with the manufacturing of oncology small molecule drugs.

The study also provides the dynamics responsible for influencing the future status of the oncology small molecule drugs market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the oncology small molecule drugs market, along with their product portfolios, enhances the reliability of this comprehensive research study.

Report Summary

The study offers a comprehensive analysis of diverse features, including production capacities, demand, product developments, revenue generation, and sales of the oncology small molecule drugs market across the globe.

A comprehensive estimate of the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of the oncology small molecule drugs during the forecast period. Price point comparison by region with the global average price is also considered in the study.

Key Questions Answered in Report

  • Which are the most lucrative oncology small molecule drugs markets?
  • Which factors will impact growth of the oncology small molecule drugs market?
  • How will changing trends impact the strategies of market players?
  • How can market players capture the low-hanging opportunities across regions?
  • Which companies are leading the oncology small molecule drugs industry?
  • What are the winning strategies of stakeholders in the market?

Analysis on Market Size Evaluation

The market has been analyzed for each segment in terms of volume (‘000 Units) and value (US$ Mn).

Estimates at global and regional levels for the oncology small molecule drugs market are available in terms of “US$ Mn” for value and in “‘000 Units” for volume. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.

Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global oncology small molecule drugs market.

Inspected Assessment on Regional Segments

Key sections have been elaborated in the report, which has helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the oncology small molecule drugs market during the forecast period.

Country-specific valuation on demand for the oncology small molecule drugs market has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions ad countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value & volume for emerging countries has also been included in the report.

In-depth Analysis on Competition Analysis

The report sheds light on leading manufacturers of oncology small molecule drugs, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in producing oncology small molecule drugs have been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permit report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which includes essentials such as product portfolios and key strategies, along with an all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the Oncology Small Molecule Drugs market domain.

Research Methodology

In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the oncology small molecule drugs industry, and reach conclusions on the future growth parameters. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the draw conclusions.

Secondary resources referred to by analysts during the preparation of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of the research report as a primary resource.

- FAQs -

As of 2019, sales of oncology small molecule drugs reached US$ 66 Bn

From 2016 to 2020, sales of oncology small molecule drugs expanded at approximately 3% CAGR

From 2021 to 2031, demand for oncology small molecule drugs is expected to surge at approximately 6% CAGR

By 2031, sales of oncology small molecule drugs will surpass US$ 120 Bn according to Fact.MR

Increasing number of cancer cases and investments in R&D of oncology drug production are the prominent demand driver for the market.

Sales of oncology small molecule drugs in China will likely capture 55% of global demand

As per Fact.MR, oncology small molecule drugs sales totaled US$ 30 Bn in the U.S as of 2019

Novartis Ag, AstraZeneca, Genentech, Pfizer, and AbbVie, are the top 5 players, accounting for 47% market share. 

Oral administration is the most preferred route of administration, clocking US$ 56 Bn in 2019

Need an Exclusive Report for your Unique Requirement?

Talk Show:

The Rise of Intelligent Packaging

Personalized, Connected and Sustainable

November 18, 2021 11:00-11:45 AM PST (USA & Canada)
This is a LIVE session
Future Market Insights MarketNgage Spring

- Our Clients -

Report Client

- Evaluate How Fact.MR's Report Can Help. -

Is the market research conducted by Fact.MR?

Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

What research methodology is followed by Fact.MR?

Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

What are the sources of secondary research?

Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

Who are the respondents for primary research?

Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

Is a sample of this report available for evaluation?

Yes, you can request a sample, and it will be sent to you through an email.